研究显示,Oniviyde 疗程可以将晚期胰腺癌患者的寿命延长近20个月。 Study suggests Onivyde regimen can extend life by nearly 20 months for advanced pancreatic cancer patients.

一项新的研究表明,Oniviyde疗法与其他药物相结合,可以帮助患晚期胰腺癌的人平均寿命延长19.5个月左右。 A new study shows that the Onivyde regimen, combined with other drugs, can help people with advanced pancreatic cancer live about 19.5 months longer on average. 年龄更小和特定肿瘤地点等因素与更好的存活率有关。 Factors like younger age and specific tumor locations were linked to better survival rates. 虽然对治疗剂量的调整有助于病人在疗程上停留更长的时间,但调查结果来自少量的样本,这表明在解释时要谨慎。 While adjustments to treatment doses helped patients stay on the regimen longer, the findings come from a small sample size, suggesting caution in interpretation.